NEW YORK, NY / ACCESSWIRE / October 12, 2021 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff. There will be no obligation or cost to you.

Yalla Group Limited (NYSE:YALA)

If you suffered a loss, contact us at: https://www.wongesq.com/pslra-1/yalla-group-limited-loss-submission-form?prid=20335&wire=1
Lead Plaintiff Deadline: October 12, 2021
Class Period: September 30, 2020 - August 9, 2021

Allegations against YALA include that: the Company overstated its user metrics and revenue and, as a result, the Company's public statements were materially false and misleading at all relevant times.

Katapult Holdings, Inc. (NASDAQ:KPLT)

If you suffered a loss, contact us at: https://www.wongesq.com/pslra-1/katapult-holdings-inc-loss-submission-form?prid=20335&wire=1
Lead Plaintiff Deadline: October 26, 2021
Class Period: December 18, 2020 - August 10, 2021

Allegations against KPLT include that: (1) Katapult was experiencing declining e-commerce retail sales and consumer spending, (2) despite Katapult's assertions that it was clear and compelling value proposition to both consumers and merchants, transforming the way nonprime consumers shop for essential goods and enabling merchant access to this underserved segment, Katapult lacked visibility into its consumers' future buying behavior; and (3) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis.

Sesen Bio, Inc. (NASDAQ:SESN)

If you suffered a loss, contact us at: https://www.wongesq.com/pslra-1/sesen-bio-inc-loss-submission-form?prid=20335&wire=1
Lead Plaintiff Deadline: October 18, 2021
Class Period: December 21, 2020 - August 17, 2021

Allegations against SESN include that: (1) Sesen Bio's clinical trial for its cancer treatment product, Vicineum, had more than 2,000 violations of trial protocol, including 215 classified as "major"; (2) three of Sesen Bio's clinical investigators were found guilty of "serious noncompliance," including "back-dating data"; (3) Sesen Bio had submitted the tainted data in connection with the Biologics License Application ("BLA") for Vicineum; (4) Sesen Bio's clinical trials showed that Vicineum leaked out into the body, leading to side effects including liver failure and liver toxicity, and increasing the risks for fatal, drug-induced liver injury; (5) as a result of the foregoing, the Company's BLA for Vicineum was not likely to be approved; (6) as a result of the foregoing, there was a reasonable likelihood that Sesen Bio would be required to conduct additional trials to support the efficacy and safety of Vicineum; and (7) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

To learn more contact Vincent Wong, Esq. either via email vw@wongesq.com or by telephone at 212.425.1140.

Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: vw@wongesq.com

SOURCE: The Law Offices of Vincent Wong